Immediate Impact
50 standout
Citing Papers
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2024 Standout
Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial
2024 Standout
Works of Alexandra Huber being referenced
International SF-36 reference values in patients with ischemic heart disease
2016
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Alexandra Huber | 142 | 193 | 103 | 174 | 26 | 502 | |
| Sufyan Sabri | 71 | 116 | 14 | 74 | 19 | 568 | |
| Ana-Maria Vranceanu | 86 | 174 | 58 | 125 | 21 | 570 | |
| Carolyn Finck | 90 | 123 | 96 | 99 | 25 | 525 | |
| Jiří Mudrák | 137 | 97 | 29 | 198 | 33 | 572 | |
| Cecilia R. Barron | 178 | 188 | 79 | 85 | 26 | 572 | |
| Elena L. Navas-Nacher | 105 | 176 | 19 | 58 | 16 | 539 | |
| Luca Vecchio | 119 | 55 | 49 | 80 | 24 | 419 | |
| Nop Ratanasiripong | 122 | 175 | 22 | 81 | 20 | 451 | |
| Yuqin Gao | 215 | 205 | 38 | 67 | 20 | 432 | |
| Éva Susánszky | 132 | 106 | 21 | 78 | 29 | 420 |
All Works
Login with ORCID to disown or claim papers
Loading papers...